Mouse Anti-GIGYF2 Recombinant Antibody (CBLG1-3170) (V2LY-1225-LY1308)
Compare
Online Inquiry
Basic Information
| Application | Note |
| ELISA | 1:100-1:1,000 |
| WB | 1:100-1:1,000 |
| IP | 1-2 µg per 100-500 µg of total protein (1 ml of cell lysate) |
| IF(ICC) | 1:50-1:500 |
Formulations & Storage [For reference only, actual COA shall prevail!]
Target
In the 4EHP-GYF2 complex, acts as a factor that bridges EIF4E2 to ZFP36/TTP, linking translation repression with mRNA decay (PubMed:31439631).
Also recruits and bridges the association of the 4EHP complex with the decapping effector protein DDX6, which is required for the ZFP36/TTP-mediated down-regulation of AU-rich mRNA (PubMed:31439631).
May act cooperatively with GRB10 to regulate tyrosine kinase receptor signaling, including IGF1 and insulin receptors (PubMed:12771153).
Cellular protein metabolic process Source: Ensembl
Feeding behavior Source: Ensembl
Homeostasis of number of cells within a tissue Source: Ensembl
Insulin-like growth factor receptor signaling pathway Source: ParkinsonsUK-UCL
Mitotic G1 DNA damage checkpoint signaling Source: Ensembl
mRNA destabilization Source: ParkinsonsUK-UCL
Multicellular organism growth Source: Ensembl
Musculoskeletal movement Source: Ensembl
Negative regulation of translation Source: MGI
Neuromuscular process controlling balance Source: Ensembl
Post-embryonic development Source: Ensembl
Posttranscriptional gene silencing Source: ParkinsonsUK-UCL
Spinal cord motor neuron differentiation Source: Ensembl
Disease susceptibility may be associated with variants affecting the gene represented in this entry. Its association with Parkinson disease is however unclear. According to a number of studies, variations affecting this gene are not a frequent cause of Parkinson disease, suggesting that GIGYF2 does not play a major role in Parkinson disease etiology (PubMed:19279319, PubMed:19429085, PubMed:19638301, PubMed:19482505, PubMed:20004041, PubMed:19321232, PubMed:20060621). A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain.
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon
$30 eGift Card
Submit a review
Loading...
Please try the standard protocols which include: protocols, troubleshooting and guide.
Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols
Custom Antibody Labeling
We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).
Online InquiryContact us
